A drug developed in type 2 diabetes could be used with profit to treat the memory loss seen in Alzheimer's disease. A team of researchers discovered that it had "significantly reversed memory loss" in an animal mouse Alzheimer's model.
The study, published in Brain Research, is making a splash because it could substantially improve the treatment of Alzheimer's disease. And this thanks to the use of a drug originally created to treat type 2 diabetes.
According to Doug Brown, director of research and development at the International Society on Alzheimer's Disease, said: "Without any new treatment in nearly 15 years, we must find new ways to fight against Alzheimer's disease . It is imperative that we explore whether drugs developed to treat other diseases could not benefit people with Alzheimer's disease and other forms of dementia. "
This approach to research could also make it much faster to obtain promising new drugs for those who need them.
Triple agonist treatment
Although the benefits of the triple-agonist antidiabetic drug are currently only observed in mice, other studies of existing drugs such as liraglutide have shown a real interest in the past. Alzheimer's disease.
This triple agonist drug works in multiple ways to protect the brain from degeneration. It combines an agonist effect on GLP-1, GIP and Glucagon receptors, all of which are growth factors.
It has indeed been shown in the past that the signaling of growth factors is impaired in the brains of patients suffering from Alzheimer's disease.
An animal model of Alzheimer's disease
APP / PS1 transgenic mice with advanced stages of Alzheimer's neurodegeneration were subjected to treatment in this study.
These transgenic mice express mutated human genes responsible for Alzheimer's disease. These genes are those that have been found in families of people who have a hereditary form of Alzheimer's disease.
In these mice, labyrinth tests, learning and memory formation were greatly enhanced by the triple agonist which increases the level of a brain growth factor, which protects the functioning of nerve cells, reduces the amount of amyloid plaques in the brain linked to Alzheimer's disease, reduces both chronic inflammation and oxidative stress and slows the loss of nerve cells
Close links diabetes and Alzheimer's disease
Type 2 diabetes is a major risk factor for Alzheimer's disease and has been implicated in the progression of the disease. Decreased insulin secretion has been associated with common degenerative brain processes in type 2 diabetes and Alzheimer's disease.
Insulin resistance has also been observed in the brains of patients with Alzheimer's disease. This resistance may play a role in the development of neurodegenerative disorders because insulin is a growth factor with neuroprotective properties.
Clinical studies with older antidiabetics have already shown very promising results in people with Alzheimer's disease or with mood disorders. The new antidiabetic with triple agonism is promising as a potential treatment for Alzheimer's disease, but further studies are needed before it is affirmed.
The results of these new multiple antagonist drugs, originally developed to treat type 2 diabetes, are very promising because they have shown consistent neuroprotective effects in several studies.